Valuation losses on securities due to fluctuations in interest rates, stock prices and foreign exchange rates
First written in FY2017. 13 of 30 entries say "Worsened", first in FY2018. Latest entry: 2026-08-03.
The Shimizu Bank moved to the "Worse" side of this theme in 2021, the same year as the typical company in this theme.
The whole theme swung hardest in 2019: 4 of 6 companies on the "Worse" side.
1 other company's latest entry also says "Worsened".
- 2026-08-03WorsenedEarnings
「Other securities △ 14,791 7,808 22,599」
The valuation difference on other securities deteriorated from negative ¥14,066 million at the end of March 2026 to negative ¥14,791 million. - FY2026Valuation differences improved, while VaR increased slightlyAnnual report
「As of 31 March 2026, VaR totaled ¥16,697 million for loans, securities, deposits and interest rate swap transactions.」
Market risk VaR edged up from ¥16,683 million in the previous fiscal year to ¥16,697 million. The valuation difference on other securities improved from negative ¥12,252 million to negative ¥9,268 million, and no impairment losses on securities were recognized during the fiscal year. - 2026-05-28WorsenedGeneral Meetings of Shareholders
「Total 264,661 278,666 △14,005」
The valuation difference on other securities was reported at negative ¥14,005 million. Because the scope and timing differ from the valuation difference of negative ¥8,199 million in the most recent canonical record, this is recorded as the valuation difference at the end of the current fiscal year rather than directly compared. The canonical thread itself remains unchanged. - FY2026-H1The valuation difference improved, while equity impairment was recognizedAnnual report
「Valuation difference on other securities Negative ¥8,199 million Impairment losses recognized during the current six-month period were ¥48 million on equities.」
The valuation difference on other securities improved from negative ¥12,252 million at the end of the previous fiscal year to negative ¥8,199 million, while ¥48 million in equity impairment losses was recognized during the current six-month period. - FY2025WorsenedAnnual report
「As of 31 March 2025, VaR totaled ¥16,683 million for loans, securities, deposits and interest rate swap transactions.」
Market risk VaR was disclosed at ¥16,683 million. The valuation difference on other securities deteriorated from negative ¥4,687 million at the end of the previous fiscal year to negative ¥12,252 million, while no impairment losses on securities were recognized during the fiscal year. - FY2025-H1WorsenedAnnual report
「Valuation difference on other securities Negative ¥7,112 million」
The valuation difference on other securities deteriorated from negative ¥4,687 million at the end of the previous fiscal year to negative ¥7,112 million. No impairment losses on securities were recognized during the current six-month period. - FY2024-Q3MitigatedAnnual report
「Valuation difference on other securities Negative ¥9,917 million」
The valuation difference on other securities improved from negative ¥11,819 million at the end of the previous fiscal year to negative ¥9,917 million. It was also disclosed that no impairment losses on securities were recognized during the first 3 quarters of the current fiscal year. - FY2024-Q2WorsenedAnnual report
「Valuation difference on other securities Negative ¥14,498 million」
The valuation difference on other securities deteriorated from negative ¥11,819 million at the end of the previous fiscal year to negative ¥14,498 million. No impairment losses on securities were recognized during the current six-month period. - FY2023WorsenedAnnual report
「As of 31 March 2023, VaR totaled ¥19,527 million for loans, securities, deposits and interest rate swap transactions.」
Market risk VaR increased from ¥15,843 million in the previous fiscal year to ¥19,527 million. The valuation difference on other securities was negative ¥11,819 million, and equity impairment losses were ¥107 million, indicating a greater impact from market fluctuations on valuations. - FY2023-Q3WorsenedAnnual report
「Total 349,350 331,712 △17,637 Impairment losses recognized in the previous fiscal year were ¥72 million on equities. No impairment losses were recognized during the first 3 quarters of the current fiscal year.」
No impairment losses on securities were recognized during the first 3 quarters of the current fiscal year, while the valuation difference on other securities was negative ¥17,637 million, widening in the direction of valuation losses from negative ¥5,941 million at the end of the previous fiscal year. - FY2023-Q2WorsenedAnnual report
「Impairment losses recognized in the previous fiscal year were ¥72 million on equities. Impairment losses recognized during the current six-month period were ¥83 million on equities.」
Equity impairment losses on securities increased from ¥72 million in the previous fiscal year to ¥83 million during the current six-month period. The valuation difference on other securities also deteriorated from negative ¥3,785 million at the end of March 2022 to negative ¥12,077 million. - FY2023-Q1WorsenedAnnual report
「Impairment losses recognized in the previous fiscal year were ¥72 million on equities. Impairment losses recognized during the first quarter of the current fiscal year were ¥79 million on equities.」
Impairment losses on securities increased from ¥72 million in the previous fiscal year to ¥79 million in the first quarter of the current fiscal year. The valuation difference on other securities also deteriorated from negative ¥5,941 million at the end of the previous fiscal year to negative ¥11,100 million. - FY2022VaR declined, while equity impairment continuedAnnual report
「As of 31 March 2022, VaR totaled ¥15,843 million for loans, securities, deposits and interest rate swap transactions. Impairment losses recognized during the fiscal year were ¥72 million on equities.」
Market risk VaR declined from ¥16,058 million in the previous fiscal year to ¥15,843 million, while ¥72 million in equity impairment losses was recognized. - FY2022-Q3Share impairment losses recorded for the cumulative third quarterAnnual report
「Impairment losses during the previous consolidated fiscal year amounted to ¥15 million on shares. Impairment losses during the cumulative third quarter of the current consolidated fiscal year amounted to ¥72 million on shares.」
After recording impairment losses of ¥15 million on shares in the previous fiscal year, the company also recorded impairment losses of ¥72 million on shares during the cumulative third quarter of the current consolidated fiscal year. - FY2022-Q2¥79 million in share impairment losses recorded in the interim periodAnnual report
「Impairment losses during the previous consolidated fiscal year amounted to ¥15 million on shares. Impairment losses during the current interim consolidated accounting period amounted to ¥79 million on shares.」
Following ¥15 million in impairment losses on shares in the previous fiscal year, ¥79 million in impairment losses on shares were recorded during the current interim consolidated accounting period, indicating that the risk of valuation losses on securities has materialised. - FY2022-Q1WorsenedAnnual report
「Impairment losses during the previous consolidated fiscal year amounted to ¥15 million on shares. Impairment losses during the cumulative first quarter of the current consolidated fiscal year amounted to ¥80 million on shares.」
Impairment losses on securities increased from ¥15 million on shares in the previous consolidated fiscal year to ¥80 million during the cumulative first quarter of the current fiscal year. - FY2021VaR increased, while impairment losses on securities fell sharplyAnnual report
「As of 31 March 2021, VaR for loans, securities, deposits, and interest rate swap transactions totaled ¥16,058 million.」
Market risk VaR increased from ¥14,126 million in the previous fiscal year to ¥16,058 million. Meanwhile, impairment losses on securities during the current fiscal year amounted to ¥15 million on shares, down sharply from ¥3,214 million in the previous fiscal year. - FY2021-Q3MaterialisedAnnual report
「Impairment losses during the previous consolidated fiscal year amounted to ¥3,214 million on shares. Impairment losses during the cumulative third quarter of the current consolidated fiscal year amounted to ¥84 million on shares.」
Following the previous fiscal year, impairment losses of ¥84 million on shares were recorded during the cumulative third quarter of the current consolidated fiscal year, indicating that the risk of valuation losses on securities has materialised. - FY2021-Q2MitigatedAnnual report
「Impairment losses during the previous consolidated fiscal year amounted to ¥3,214 million on shares. No impairment losses were recorded during the current interim consolidated accounting period.」
After recording impairment losses of ¥3,214 million on shares in the previous fiscal year, no impairment losses on securities were recorded during the current interim consolidated accounting period. Valuation differences on securities also increased from ¥660 million at the end of the previous fiscal year to ¥3,297 million. - FY2021-Q1MitigatedAnnual report
「There were no impairment losses during the nine-month period of the current consolidated fiscal year.」
After recording impairment losses of ¥3,214 million on shares in the previous fiscal year, no impairment losses on securities were recorded during the cumulative first quarter of the current consolidated fiscal year. Valuation differences on other securities also increased from ¥660 million at the end of the previous fiscal year to ¥2,237 million. - FY2020MaterialisedAnnual report
「Impairment losses during the current consolidated fiscal year amounted to ¥3,214 million on shares.」
The risk of valuation losses on securities due to market price fluctuations materialised as impairment losses of ¥3,214 million on shares and losses on the sale of securities of ¥2,108 million. - FY2020-Q3WorsenedAnnual report
「Impairment losses during the cumulative third quarter of the current consolidated fiscal year amounted to ¥256 million on shares.」
In connection with the risk of valuation losses on securities, impairment losses on shares increased from ¥148 million for the cumulative second quarter to ¥256 million. - FY2020-Q2MaterialisedAnnual report
「Impairment losses during the current interim consolidated accounting period amounted to ¥148 million on shares.」
In connection with the risk of valuation losses on securities, impairment losses of ¥148 million on shares were recorded during the current interim consolidated accounting period. - FY2020-Q1MaterialisedAnnual report
「Impairment losses during the cumulative first quarter of the current consolidated fiscal year amounted to ¥152 million on shares.」
In connection with the risk of valuation losses on securities, impairment losses of ¥152 million on shares were recorded during the cumulative first quarter of the current consolidated fiscal year. Meanwhile, valuation differences on other securities increased from ¥3,564 million at the end of the previous fiscal year to ¥4,324 million. - FY2019MitigatedAnnual report
「As of 31 March 2019, VaR for loans, securities, deposits, and interest rate swap transactions totaled ¥14,126 million.」
Market risk VaR for major financial instruments was ¥14,126 million, down from ¥18,919 million in the previous fiscal year. Valuation differences on other securities also decreased from ¥3,352 million at the end of the previous fiscal year to ¥2,605 million. - FY2019-Q3WorsenedAnnual report
「Valuation differences on other securities 3,352 383」
Valuation differences on other securities decreased from ¥3,352 million at the end of the previous fiscal year to ¥383 million at the end of the current third quarter. Valuation differences on other securities also totaled ¥410 million, indicating that the reduction in valuation differences is continuing. No impairment losses on securities were recorded during the cumulative third quarter of the current consolidated fiscal year. - FY2019-Q2Further decrease in valuation differences on securitiesAnnual report
「Valuation differences on other securities 3,352 1,562」
Valuation differences on other securities decreased by ¥1,790 million from ¥3,352 million at the end of the previous fiscal year to ¥1,562 million at the end of the current interim period. - FY2019-Q1Decrease in valuation differences on securitiesAnnual report
「Valuation differences on other securities 3,352 2,513」
Valuation differences on other securities decreased from ¥3,352 million at the end of the previous fiscal year to ¥2,513 million at the end of the current first quarter. The company also stated that no impairment losses on securities were recorded during the current first quarter. - FY2018WorsenedAnnual report
「As of 31 March 2018, VaR for loans, securities, deposits, and interest rate swap transactions totaled ¥18,919 million.」
Market risk VaR was disclosed at ¥18,919 million, up from ¥17,895 million reported for the previous fiscal year. - FY2017First statedAnnual report
「The Bank holds marketable securities. Sharp price fluctuations caused by movements in interest rates, share prices, and foreign exchange rates may result in valuation losses on its securities holdings, potentially affecting business performance.」
The company discloses the risk of price fluctuations in securities and quantitatively reports market risk in the financial instruments notes as VaR of ¥17,895 million.